INS and sarcopenia: Thus, gaining control of these initial signals and processes in obese, insulin resistant, and/or aging skeletal muscle with mTOR antagonists (e.g. rapamycin, metformin), may be beneficial to limiting sarcopenia and sarcopenia-related dysfunction.